Published in Clin Cancer Res on August 01, 2002
Inhibition of NF-kappaB signaling by quinacrine is cytotoxic to human colon carcinoma cell lines and is synergistic in combination with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or oxaliplatin. J Biol Chem (2010) 1.10
Association of FAS (TNFRSF6)-670 gene polymorphism with villous atrophy in coeliac disease. World J Gastroenterol (2004) 0.75
Fatty acid-binding protein 1 is preferentially lost in microsatellite instable colorectal carcinomas and is immune modulated via the interferon γ pathway. Mod Pathol (2016) 0.75
Neighbours of cancer-related proteins have key influence on pathogenesis and could increase the drug target space for anticancer therapies. NPJ Syst Biol Appl (2017) 0.75
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell (2004) 10.89
Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance. Blood (2007) 4.91
Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell (2004) 4.17
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol (2011) 3.95
A test of climate, sun, and culture relationships from an 1810-year Chinese cave record. Science (2008) 3.94
Norovirus and histo-blood group antigens: demonstration of a wide spectrum of strain specificities and classification of two major binding groups among multiple binding patterns. J Virol (2005) 3.74
Racial survival disparity in head and neck cancer results from low prevalence of human papillomavirus infection in black oropharyngeal cancer patients. Cancer Prev Res (Phila) (2009) 3.70
Structural basis for the recognition of blood group trisaccharides by norovirus. J Virol (2007) 3.58
MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. J Biol Chem (2010) 2.85
Non-small cell lung cancer, version 2.2013. J Natl Compr Canc Netw (2013) 2.56
Good manufacturing practice production of self-complementary serotype 8 adeno-associated viral vector for a hemophilia B clinical trial. Hum Gene Ther (2011) 2.29
Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res (2004) 2.28
An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737. Blood (2011) 2.16
Structural basis for the receptor binding specificity of Norwalk virus. J Virol (2008) 1.82
The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma. Cancer Res (2009) 1.79
Effect of combined laser acupuncture on knee osteoarthritis: a pilot study. Lasers Med Sci (2008) 1.77
Non-small cell lung cancer, version 1.2015. J Natl Compr Canc Netw (2014) 1.71
Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells. Clin Cancer Res (2004) 1.68
Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy. Cancer Res (2010) 1.64
Lack of correlation between the histologic and magnetic resonance imaging results of optic nerve involvement in eyes primarily enucleated for retinoblastoma. Ophthalmology (2009) 1.54
Retracted FOXO1a acts as a selective tumor suppressor in alveolar rhabdomyosarcoma. J Cell Biol (2005) 1.51
Warburg effect in chemosensitivity: targeting lactate dehydrogenase-A re-sensitizes taxol-resistant cancer cells to taxol. Mol Cancer (2010) 1.50
Hedgehog signaling drives cellular survival in human colon carcinoma cells. Cancer Res (2010) 1.50
Phase I study of combination topotecan and carboplatin in pediatric solid tumors. J Clin Oncol (2002) 1.47
Genetic and phenotypic characterization of GII-4 noroviruses that circulated during 1987 to 2008. J Virol (2010) 1.46
Modern treatment of lung cancer: case 1. Amplification and mutation of the epidermal growth factor receptor in metastatic lung cancer with remission from gefitinib. J Clin Oncol (2005) 1.46
Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells. Antimicrob Agents Chemother (2004) 1.41
Improving the histopathologic diagnosis of pediatric malignancies in a low-resource setting by combining focused training and telepathology strategies. Pediatr Blood Cancer (2012) 1.39
Spike protein VP8* of human rotavirus recognizes histo-blood group antigens in a type-specific manner. J Virol (2012) 1.38
Rapid immune recovery and graft-versus-host disease-like engraftment syndrome following adoptive transfer of Costimulated autologous T cells. Clin Cancer Res (2009) 1.38
Topotecan combination chemotherapy in two new rodent models of retinoblastoma. Clin Cancer Res (2005) 1.37
Blocking Hedgehog survival signaling at the level of the GLI genes induces DNA damage and extensive cell death in human colon carcinoma cells. Cancer Res (2011) 1.35
Overcoming trastuzumab resistance in breast cancer by targeting dysregulated glucose metabolism. Cancer Res (2011) 1.35
B7-H4 expression associates with cancer progression and predicts patient's survival in human esophageal squamous cell carcinoma. Cancer Immunol Immunother (2011) 1.34
Prediction of antimicrobial peptides based on sequence alignment and feature selection methods. PLoS One (2011) 1.34
Functional analysis of the heat shock regulator HrcA of Chlamydia trachomatis. J Bacteriol (2002) 1.33
CPAF: a Chlamydial protease in search of an authentic substrate. PLoS Pathog (2012) 1.33
Crystallography of a Lewis-binding norovirus, elucidation of strain-specificity to the polymorphic human histo-blood group antigens. PLoS Pathog (2011) 1.31
Myc regulates aggresome formation, the induction of Noxa, and apoptosis in response to the combination of bortezomib and SAHA. Blood (2008) 1.31
Sigma28 RNA polymerase regulates hctB, a late developmental gene in Chlamydia. Mol Microbiol (2003) 1.29
High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma. Cancer (2004) 1.29
A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation. Cancer Chemother Pharmacol (2010) 1.27
Cryo-EM structure of a novel calicivirus, Tulane virus. PLoS One (2013) 1.26
Zinc and prostate cancer: a critical scientific, medical, and public interest issue (United States). Cancer Causes Control (2005) 1.25
Rottlerin sensitizes colon carcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis via uncoupling of the mitochondria independent of protein kinase C. Cancer Res (2003) 1.24
Mutational analysis of the Chlamydia trachomatis dnaK promoter defines the optimal -35 promoter element. Nucleic Acids Res (2003) 1.24
Glucose oxidation modulates anoikis and tumor metastasis. Mol Cell Biol (2012) 1.23
Cardiovascular events in patients taking varenicline: a case series from intensive postmarketing surveillance in New Zealand. Drug Saf (2012) 1.21
Targeting the p53 pathway in retinoblastoma with subconjunctival Nutlin-3a. Cancer Res (2011) 1.21
UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan. J Clin Oncol (2007) 1.20
Reactive oxygen species regulate caspase activation in tumor necrosis factor-related apoptosis-inducing ligand-resistant human colon carcinoma cell lines. Cancer Res (2005) 1.20
Stalling the engine of resistance: targeting cancer metabolism to overcome therapeutic resistance. Cancer Res (2013) 1.19
Rotavirus VP8*: phylogeny, host range, and interaction with histo-blood group antigens. J Virol (2012) 1.18
The GLI genes as the molecular switch in disrupting Hedgehog signaling in colon cancer. Oncotarget (2011) 1.17
In vivo selection of hematopoietic progenitor cells and temozolomide dose intensification in rhesus macaques through lentiviral transduction with a drug resistance gene. J Clin Invest (2009) 1.17
Molecular mechanism of tryptophan-dependent transcriptional regulation in Chlamydia trachomatis. J Bacteriol (2006) 1.17
A pilot study of protracted topotecan dosing using a pharmacokinetically guided dosing approach in children with solid tumors. Clin Cancer Res (2003) 1.17
The Cancer Care Monitor: psychometric content evaluation and pilot testing of a computer administered system for symptom screening and quality of life in adult cancer patients. J Pain Symptom Manage (2003) 1.16
cDNA microarray gene expression profiling of hedgehog signaling pathway inhibition in human colon cancer cells. PLoS One (2010) 1.15
Mitotic deregulation by survivin in ErbB2-overexpressing breast cancer cells contributes to Taxol resistance. Clin Cancer Res (2009) 1.13
In silico prediction and functional validation of sigma28-regulated genes in Chlamydia and Escherichia coli. J Bacteriol (2006) 1.13
Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children: results of a multiinstitutional study (SJHG-98). Cancer (2005) 1.12
CD137 promotes proliferation and survival of human B cells. J Immunol (2009) 1.12
Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry. J Mol Diagn (2008) 1.11
Description and predictors of direct and indirect costs of pain reported by cancer patients. J Pain Symptom Manage (2003) 1.11
Staurosporine induces necroptotic cell death under caspase-compromised conditions in U937 cells. PLoS One (2012) 1.11
Subconjunctival carboplatin and systemic topotecan treatment in preclinical models of retinoblastoma. Cancer (2010) 1.11
Human milk contains elements that block binding of noroviruses to human histo-blood group antigens in saliva. J Infect Dis (2004) 1.10
Norovirus P particle efficiently elicits innate, humoral and cellular immunity. PLoS One (2013) 1.10
Emergence of the GII4/2006b variant and recombinant noroviruses in China. J Med Virol (2008) 1.10
Inhibition of NF-kappaB signaling by quinacrine is cytotoxic to human colon carcinoma cell lines and is synergistic in combination with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or oxaliplatin. J Biol Chem (2010) 1.10
Casein kinase II (CK2) enhances death-inducing signaling complex (DISC) activity in TRAIL-induced apoptosis in human colon carcinoma cell lines. Oncogene (2005) 1.09
Histone deacetylase inhibitors enhance lexatumumab-induced apoptosis via a p21Cip1-dependent decrease in survivin levels. Cancer Res (2007) 1.09
Receptor tyrosine kinase ErbB2 translocates into mitochondria and regulates cellular metabolism. Nat Commun (2012) 1.06
Sparse logistic regression with Lp penalty for biomarker identification. Stat Appl Genet Mol Biol (2007) 1.06
Thymomas and thymic carcinomas: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2013) 1.06
Aly and THO are required for assembly of the human TREX complex and association of TREX components with the spliced mRNA. Nucleic Acids Res (2012) 1.06
Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of acute leukemias. Clin Cancer Res (2009) 1.05
Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin's disease. J Clin Oncol (2004) 1.05
Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer (2010) 1.05
A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer (2010) 1.04
Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program. Pediatr Blood Cancer (2011) 1.04
Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program. Pediatr Blood Cancer (2010) 1.03
Mutational analysis of the promoter recognized by Chlamydia and Escherichia coli sigma(28) RNA polymerase. J Bacteriol (2006) 1.03
ATP modulates PTEN subcellular localization in multiple cancer cell lines. Hum Mol Genet (2008) 1.03
B7-H3 silencing increases paclitaxel sensitivity by abrogating Jak2/Stat3 phosphorylation. Mol Cancer Ther (2011) 1.03
Emerging metabolic targets in cancer therapy. Front Biosci (Landmark Ed) (2011) 1.02
Testing the annual nature of speleothem banding. Sci Rep (2013) 1.02
A candidate dual vaccine against influenza and noroviruses. Vaccine (2011) 1.01
ROR1 expression is not a unique marker of CLL. Hematol Oncol (2011) 1.01
Downregulation of missing in metastasis gene (MIM) is associated with the progression of bladder transitional carcinomas. Cancer Invest (2007) 1.01